Sama Pharmaceutical

Sama Pharmaceutical is a long-standing South Korean pharmaceutical company established in 1945, primarily known for its dominance in the pediatric and respiratory medicine markets. The company specializes in the development, manufacturing, and marketing of prescription (ETC) and over-the-counter (OTC) drugs, with a particular focus on 'Incrementally Modified Drugs' (IMDs) that improve patient compliance in children. The company operates a state-of-the-art EU-GMP compliant manufacturing facility in Wonju, Gangwon-do, and maintains a robust R&D center in Seoul. Their product portfolio includes market-leading treatments for asthma, allergic rhinitis, and respiratory infections, such as the Codaewon and Aristocort lines. Sama is recognized for its conservative but stable financial management and its niche leadership in the domestic Korean pediatric market.